Core Viewpoint - Coeptis Therapeutics Holdings, Inc. has announced that its registration statement for a merger with Z Squared Inc. has been declared effective by the SEC, and it will begin mailing the definitive proxy statement/prospectus to stockholders ahead of the Stockholder Meeting scheduled for January 30, 2026 [1] Company Overview - Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical and technology company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases [3] - The company operates through its subsidiaries, including Coeptis Pharmaceuticals, GEAR Therapeutics, SNAP Biosciences, and Coeptis Technologies [3] Therapeutic Portfolio - Coeptis's therapeutic portfolio includes assets licensed from Deverra Therapeutics, featuring an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage natural killer cell therapy technology [4] - The company is also developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh, alongside GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and the Karolinska Institute [4] Technology Division - Coeptis has established a Technology Division aimed at enhancing operational capabilities through advanced technologies, including AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group [5] Z Squared Overview - Z Squared is focused on building a sustainable cryptocurrency mining operation, with 9,000 ASIC miners targeting Dogecoin and Litecoin, addressing market caps of $20 billion and $6 billion respectively [7] Stockholder Meeting - The Stockholder Meeting for the merger transaction will be held on January 30, 2026, with notices being mailed to stockholders of record as of January 2, 2026 [1]

Core Points - Coeptis Therapeutics Holdings, Inc. has extinguished its convertible note with YA II PN, Ltd, clearing its outstanding debt obligations to Yorkville [1][2] - The CEO stated that this action strengthens the company's capital structure and positions it well for long-term goals, including potential operations in the cryptocurrency space [2] - Coeptis focuses on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases through its subsidiaries [3][4] Company Overview - Coeptis Therapeutics Holdings includes subsidiaries such as Coeptis Pharmaceuticals, GEAR Therapeutics, SNAP Biosciences, and Coeptis Technologies, emphasizing biopharmaceutical and technology advancements [3] - The therapeutic portfolio includes assets licensed from Deverra Therapeutics, featuring an allogeneic cellular immunotherapy platform and clinical-stage NK cell therapy technology [4] - Coeptis is also developing a universal, multi-antigen CAR technology in collaboration with the University of Pittsburgh and other distinguished medical researchers [4] Technology Division - Coeptis has established a Technology Division aimed at enhancing operational capabilities through advanced technologies, including AI-powered marketing software and robotic process automation tools [5] - These technologies are intended to optimize business processes and improve overall efficiency [5] Compliance and Standards - The company is headquartered in Wexford, PA, and is committed to advancing its mission within the regulatory framework set by the FDA, ensuring compliance and high standards of patient care [6]

Core Insights - COEPTIS, Inc. has established a new co-working technology hub in India in partnership with NexGenAI Solutions Group and Ishvara Tech Consulting LLP, aimed at enhancing access to AI, blockchain, biopharma, and defense technologies [1][2][3] Company Overview - COEPTIS is a pioneering technology firm focused on innovative biotechnology solutions, with a strong emphasis on developing advanced cell therapy platforms for various diseases [8][9] - The company has recently expanded its technology division, which includes AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group [10] Strategic Initiatives - The new India hub will focus on several key initiatives, including Research & Development, AI marketing strategy execution, crypto strategy execution, and advanced blockchain applications [4] - The hub is designed to support the development and integration of the NXG Token across digital platforms, enhancing the blockchain ecosystem and exploring monetization strategies rooted in data analytics and automation [4] Recent Achievements - COEPTIS has recently acquired the NexGenAI Affiliates Network platform and signed contracts valued at $2.3 million, including a $600,000 deal with NUBURU, Inc., indicating strong demand for its AI-powered marketing software [3][4] Infrastructure and Facilities - The India hub features a 60-seat capacity, expandable to 100, with modern amenities including executive cabins, conference rooms, and high-speed fiber optic internet [6]